Literature DB >> 8397768

The IL-2/IL-2 receptor system: a target for rational immune intervention.

T A Waldmann1.   

Abstract

The expression of interleukin 2 (IL-2), induction of its multisubunit receptor and subsequent interplay of this ligand with its receptor are pivotal events in T-cell activation. Our present understanding of the normal IL-2/IL-2R system and of disorders in this network in disease opens the possibility for more specific immune intervention. Thomas Waldmann discusses the clinical application of IL-2, agents that inhibit IL-2 synthesis and action, and how the anti-IL-2 receptor-directed therapy provides a novel perspective for prevention of allograft rejection and for treatment of graft versus host disease, select autoimmune disorders and certain neoplastic diseases.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8397768     DOI： 10.1016/0167-5699(93)90043-K

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


  32 in total

Review 1.  Tregs in T cell vaccination: exploring the regulation of regulation.

Authors:  Irun R Cohen; Francisco J Quintana; Avishai Mimran
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

2.  Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.

Authors:  Unsong Oh; Gregg Blevins; Caitlin Griffith; Nancy Richert; Dragan Maric; C Richard Lee; Henry McFarland; Steven Jacobson
Journal:  Arch Neurol       Date:  2009-04

Review 3.  Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.

Authors:  Thomas A Waldmann
Journal:  J Clin Immunol       Date:  2007-01-11       Impact factor: 8.317

4.  Drug combination therapy of systemic lupus erythematosus.

Authors:  P A Miescher; H Favre; R Lemoine; Y P Huang
Journal:  Springer Semin Immunopathol       Date:  1994

5.  NMR characterization of interleukin-2 in complexes with the IL-2Ralpha receptor component, and with low molecular weight compounds that inhibit the IL-2/IL-Ralpha interaction.

Authors:  S Donald Emerson; Robert Palermo; Chao-Min Liu; Jefferson W Tilley; Li Chen; Waleed Danho; Vincent S Madison; David N Greeley; Grace Ju; David C Fry
Journal:  Protein Sci       Date:  2003-04       Impact factor: 6.725

6.  Interleukin 2 induces CD8+ T cell-mediated suppression of human immunodeficiency virus replication in CD4+ T cells and this effect overrides its ability to stimulate virus expression.

Authors:  A L Kinter; S M Bende; E C Hardy; R Jackson; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

7.  Evidence for a critical role for the cytoplasmic region of the interleukin 2 (IL-2) receptor gamma chain in IL-2, IL-4, and IL-7 signalling.

Authors:  A Kawahara; Y Minami; T Taniguchi
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

8.  Tyrosine kinase-dependent and -independent events induced by interleukin-2 stimulation: interleukin-2-mediated NO production required for the induction of lymphokine-activated killer cell activity in rat splenocytes is tyrosine kinase independent.

Authors:  A Juretic; G C Spagnoli; H Hörig; R Shipman; T Kocher; M Samija; M Turic; D Eljuga; F Harder; M Heberer
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

9.  Pretreatment with enteral cholestyramine prevents suppression of the cellular immune system after partial hepatectomy.

Authors:  P A Van Leeuwen; M A Boermeester; A P Houdijk; S Meyer; M A Cuesta; R I Wesdorp; M L Rodrick; D W Wilmore
Journal:  Ann Surg       Date:  1995-03       Impact factor: 12.969

10.  Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application.

Authors:  G I Kirchner; A Franzke; J Buer; W Beil; M Probst-Kepper; F Wittke; K Overmann; S Lassmann; R Hoffmann; H Kirchner; A Ganser; J Atzpodien
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.